Skip to Content
Merck
CN
  • Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer.

Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer.

Molecular biology of the cell (2015-09-05)
Christopher C Valley, Donna J Arndt-Jovin, Narain Karedla, Mara P Steinkamp, Alexey I Chizhik, William S Hlavacek, Bridget S Wilson, Keith A Lidke, Diane S Lidke
ABSTRACT

Mutations within the epidermal growth factor receptor (EGFR/erbB1/Her1) are often associated with tumorigenesis. In particular, a number of EGFR mutants that demonstrate ligand-independent signaling are common in non-small cell lung cancer (NSCLC), including kinase domain mutations L858R (also called L834R) and exon 19 deletions (e.g., ΔL747-P753insS), which collectively make up nearly 90% of mutations in NSCLC. The molecular mechanisms by which these mutations confer constitutive activity remain unresolved. Using multiple subdiffraction-limit imaging modalities, we reveal the altered receptor structure and interaction kinetics of NSCLC-associated EGFR mutants. We applied two-color single quantum dot tracking to quantify receptor dimerization kinetics on living cells and show that, in contrast to wild-type EGFR, mutants are capable of forming stable, ligand-independent dimers. Two-color superresolution localization microscopy confirmed ligand-independent aggregation of EGFR mutants. Live-cell Förster resonance energy transfer measurements revealed that the L858R kinase mutation alters ectodomain structure such that unliganded mutant EGFR adopts an extended, dimerization-competent conformation. Finally, mutation of the putative dimerization arm confirmed a critical role for ectodomain engagement in ligand-independent signaling. These data support a model in which dysregulated activity of NSCLC-associated kinase mutants is driven by coordinated interactions involving both the kinase and extracellular domains that lead to enhanced dimerization.

MATERIALS
Product Number
Brand
Product Description

Roche
Anti-HA-Biotin, High Affinity (3F10), from rat IgG1